Home > Insider Trading > Filing (0001628280-25-016684)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831097	Agilon Health Inc.	AGL	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1446919	A. Jeffrey Schwaneke	C/O Agilon Health, Inc. 440 Polaris Parkway, Suite 550 Westerville OH 43082	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-11-29	22,300	$11.22	22,300	No	4	P	Indirect	By trust
Common Stock	Acquisiton	2025-04-01	428,922	$0.00	1,130,552	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By trust
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options (Right to buy)	Acquisiton	2025-04-01	673,077	$0.00	673,077	$4.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
673,077		2035-04-01	No	4	A	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.12 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
This transaction was originally reported in November 2023 and is hereby amended to clarify that the shares were purchased by and are held in the Schwaneke Family Joint Spousal Trust.
Restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
Includes restricted stock units.
Options that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.